Javascript must be enabled to continue!
Diagnostic Accuracy of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer: A Systematic Review and Meta-analysis
View through CrossRef
Abstract
Background
KRAS mutation status is an important biomarker in rectal cancer, with implications for prognosis and treatment response. MRI-based radiomics has emerged as a non-invasive approach for predicting tumor genotypes. However, the diagnostic performance of MRI radiomics for predicting KRAS mutation status remains unclear. This study aimed to evaluate the diagnostic accuracy of MRI radiomics for predicting KRAS mutations in rectal cancer.
Methods
A systematic search of PubMed, Cochrane Library, Scopus, and Web of Science was performed through July 2025. Diagnostic test accuracy studies evaluating MRI-based radiomics or artificial intelligence models for predicting KRAS mutation status in adult patients with rectal cancer were included, using molecular testing as the reference standard. Risk of bias was assessed using the QUADAS-2 tool. Pooled sensitivity and specificity were estimated using a bivariate random-effects model.
Results
Seven studies involving 1,224 patients were included. The pooled sensitivity was 0.736 (95% CI: 0.697–0.772) and the pooled specificity was 0.645 (95% CI: 0.586–0.701). The false positive rate was 0.355 (95% CI: 0.299–0.414). The area under the hierarchical summary receiver operating characteristic curve was 0.754, with a normalized partial AUC of 0.666. Between-study heterogeneity ranged from low to moderate depending on the estimation method (I² = 8.4%–53.3%).
Conclusion
MRI radiomics demonstrates moderate diagnostic accuracy for predicting KRAS mutation status in rectal cancer and may serve as a promising non-invasive biomarker for preoperative molecular stratification. Further large-scale studies with external validation are required to confirm its clinical utility.
Key points and Clinical relevance statement
Question
Can MRI radiomics noninvasively predict Kirsten rat sarcoma(KRAS) viral oncogene homolog mutation status in rectal cancer before treatment planning?
Findings
In seven studies including 1,224 patients, MRI radiomics showed moderate accuracy for mutation prediction, with 0.74 sensitivity and 0.65 specificity.
Clinical Relevance Statement
Preoperative MRI radiomics offers a noninvasive complement to tissue testing for molecular stratification in rectal cancer, supporting treatment planning and reducing the risk of underrepresenting whole-tumor heterogeneity.
Title: Diagnostic Accuracy of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer: A Systematic Review and Meta-analysis
Description:
Abstract
Background
KRAS mutation status is an important biomarker in rectal cancer, with implications for prognosis and treatment response.
MRI-based radiomics has emerged as a non-invasive approach for predicting tumor genotypes.
However, the diagnostic performance of MRI radiomics for predicting KRAS mutation status remains unclear.
This study aimed to evaluate the diagnostic accuracy of MRI radiomics for predicting KRAS mutations in rectal cancer.
Methods
A systematic search of PubMed, Cochrane Library, Scopus, and Web of Science was performed through July 2025.
Diagnostic test accuracy studies evaluating MRI-based radiomics or artificial intelligence models for predicting KRAS mutation status in adult patients with rectal cancer were included, using molecular testing as the reference standard.
Risk of bias was assessed using the QUADAS-2 tool.
Pooled sensitivity and specificity were estimated using a bivariate random-effects model.
Results
Seven studies involving 1,224 patients were included.
The pooled sensitivity was 0.
736 (95% CI: 0.
697–0.
772) and the pooled specificity was 0.
645 (95% CI: 0.
586–0.
701).
The false positive rate was 0.
355 (95% CI: 0.
299–0.
414).
The area under the hierarchical summary receiver operating characteristic curve was 0.
754, with a normalized partial AUC of 0.
666.
Between-study heterogeneity ranged from low to moderate depending on the estimation method (I² = 8.
4%–53.
3%).
Conclusion
MRI radiomics demonstrates moderate diagnostic accuracy for predicting KRAS mutation status in rectal cancer and may serve as a promising non-invasive biomarker for preoperative molecular stratification.
Further large-scale studies with external validation are required to confirm its clinical utility.
Key points and Clinical relevance statement
Question
Can MRI radiomics noninvasively predict Kirsten rat sarcoma(KRAS) viral oncogene homolog mutation status in rectal cancer before treatment planning?
Findings
In seven studies including 1,224 patients, MRI radiomics showed moderate accuracy for mutation prediction, with 0.
74 sensitivity and 0.
65 specificity.
Clinical Relevance Statement
Preoperative MRI radiomics offers a noninvasive complement to tissue testing for molecular stratification in rectal cancer, supporting treatment planning and reducing the risk of underrepresenting whole-tumor heterogeneity.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract
KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found i...
Abstract 2441: The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy
Abstract 2441: The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy
Abstract
Background:
KRAS-driven cancer represents ∼25% of cancers, with high rates in pancreatic cancer (PDAC), colorect...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent
Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent
Abstract
KRAS mutations are highly prevalent across many different cancer types. Recent advancements in KRAS-targeted drugs, such as the FDA-approved KRAS(G12C) inhi...
Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract
Background
Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer
Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer
Abstract
Until recently, efforts to pharmacologically target KRAS have been unsuccessful due to its small binding pocket, high affinity for GTP, and redundant mechan...

